Analyzing the cytokine profile and microbiome in Darier's Disease
Official title: Characterization of the Cytokine Profile and the Microbiome in Darier's Disease: Towards New Therapeutic Perspectives.
Run by University Hospital, Toulouse · NCT06614777 · Data updated 2026-11-12
This study is testing how the bacteria on the skin and certain immune signals differ between healthy and affected areas in people with Darier's Disease to better understand the condition and find new treatment options.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse, Centre Hospitalier Universitaire de Toulouse) |
| Status | Recruiting |
| Started | November 4, 2024 |
| Main results expected | September 25, 2025 |
| Study ends | September 25, 2025 |
| Registry record updated | December 11, 2024 |
| Trial ID | NCT06614777 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and over with a clinical diagnosis of moderate to severe Darier's Disease.
✕Probably not a fit
Patients with other inflammatory skin conditions or those currently undergoing specific treatments that may interfere with the study will not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to investigate the differences in the microbiota of the skin in patients with Darier's Disease by comparing non-lesional and lesional areas. It will involve skin biopsies and blood extraction from participants to analyze the cytokine profiles and microbial signatures associated with the disease. The study builds on previous findings that suggest a correlation between specific bacteria and the severity of skin lesions in Darier's Disease. By understanding these relationships, the research hopes to shed light on the underlying mechanisms of inflammation and potential therapeutic targets.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for managing inflammation and skin lesions in patients with Darier's Disease.
How similar studies have gone: Previous studies have shown promising results in understanding the microbiome and cytokine profiles in related skin conditions, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 or over, * MD (clinical diagnosis), * MD moderate to severe, * Person affiliated or beneficiary of a social security scheme, * Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). Exclusion Criteria: * Other inflammatory dermatological diseases : atopic dermatitis, psoriasis and lichen planus, * Skin superinfection (clinical diagnosis), * Treatment with a biotherapy, in progress or in the 12 weeks preceding inclusion, * Treatment with oral retinoids introduced in the 6 months preceding inclusion, * Application of tacrolimus to the areas or to more than 30% of the body surface, * Application of topical corticosteroids to the areas or to more than 30% of the body surface, within 2 weeks preceding inclusion, * Oral corticosteroid therapy in the 2 weeks preceding inclusion, * Application of topical retinoids to the areas in the 2 weeks prior to inclusion, * Oral and/or topical antibiotic therapy in the 2 weeks preceding inclusion, * Local antiseptic in the 2 weeks preceding inclusion, * Local keratolytics on areas within 5 days preceding inclusion.
Where it's running
-
University Hospital of Toulouse
Toulouse, Centre Hospitalier Universitaire de Toulouse, France Recruiting
Study contacts
- Principal investigator: Juliette Mazereeuw-hautier, MD — University Hospital of Toulouse
- Study coordinator: Nadège ALGANS, PM
- Email: algans.n@chu-toulouse.fr
- Phone: 0561777204
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.